JAMA: Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 A Randomized Clinical Trial


Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD4; Nina Gentile, MD5; Sean Collins, MD, MSci4; Matthew William McCarthy, MD6; Dushyantha Jayaweera, MD7; Mario Castro, MD, MPH8; Mark Sulkowski, MD9; Kathleen McTigue, MD, MPH, MS10; Florence Thicklin11; G. Michael Felker, MD, MHS1,2; Adit A. Ginde, MD, MPH12; Carolyn T. Bramante, MD, MPH3; Alex J. Slandzicki, MD13; Ahab Gabriel, MD14; Nirav S. Shah, MD, MPH15; Leslie A. Lenert, MD, MS16; Sarah E. Dunsmore, PhD17; Stacey J. Adam, PhD18; Allison DeLong, BS1; George Hanna, MD19; April Remaly, BA1; Rhonda Wilder, MS1; Sybil Wilson, RN1; Elizabeth Shenkman, PhD20; Adrian F. Hernandez, MD, MHS1,2; for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators

Author Affiliations Article Information

JAMA. Published online October 21, 2022. doi:10.1001/jama.2022.18590

Key Points

Question  Does ivermectin, 400 μg/kg, daily for 3 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients in the US with symptomatic mild to moderate COVID-19?

Findings  In this double-blinded, randomized, placebo-controlled platform trial conducted in the US during a period of Delta and Omicron variant predominance, and that included 1591 adult outpatients with COVID-19, the posterior probability of improvement in time to recovery in those treated with ivermectin vs placebo had a hazard ratio of 1.07, with a posterior probability of benefit of .91. This did not meet the prespecified threshold of posterior probability greater than .95.

Meaning  These findings do not support the use of ivermectin in outpatients with mild to moderate COVID-19.




This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s